Our recent studies indicate that a class I HDAC inhibitor (HDACi), SNDX-275 exhibits strong anti-MM activities via enhanced DNA damage response and induction of apoptosis [28]. This evidence concerns the gene HDAC9 and Miyoshi myopathy.